Brilinta（ACS/急性冠症候群）：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 18
3.1.3 Prognosis 19
3.1.4 Quality of Life 20
3.2 Symptoms 20
4 Disease Management 22
4.1 Treatment Overview 22
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Brilinta (ticagrelor) 34
6.1 Overview 34
6.2 Efficacy 35
6.3 Safety 36
6.4 SWOT Analysis 37
6.5 Forecast 37
7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 44
7.3 Methodology 48
7.4 Forecasting Methodology 48
7.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 48
7.4.2 Diagnosed Acute Coronary Syndrome Patients 49
7.4.3 Percent Drug-Treated Patients 50
7.4.4 General Pricing Assumptions 50
7.4.5 Individual Drug Assumptions 52
7.4.6 Generic Erosion 52
7.5 Physicians and Specialists Included in this Study 53
7.6 About the Authors 56
7.6.1 Author 56
7.6.2 Reviewer 56
7.6.3 Global Head of Healthcare 57
7.7 About GlobalData 58
7.8 Disclaimer 58